{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:54:41Z","timestamp":1782604481094,"version":"3.54.5"},"reference-count":20,"publisher":"Bentham Science Publishers Ltd.","issue":"3","license":[{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2019,9,17]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Immune checkpoint inhibitors (CPIs) are new promising anti-cancer drugs that\nblock negative costimulation of T-cells leading to an enhanced anti-tumor immune response. Pembrolizumab,\nan a monoclonal antibody, targeting the programmed cell death protein 1 (PD-1) pathway. CPIs\nhave been associated with a number of immune-related adverse events (AEs), including musculoskeletal\nand rheumatic disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p> To present a case with lung adenocarcinoma treated with pembrolizumab, which developed inflammatory\narthritis and fasciitis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Case Report:<\/jats:title>\n<jats:p>A 73-year-old male patient was referred to the rheumatology outpatient clinic with complaints\nof pain in the pretibial area, pain and swelling in both ankles joints and the right f\u0131rst metacarpophalangeal\n(MCP) joint. Three months ago he had diagnosed with lung adenocarcinoma and pembrolizumab was started.\nLocomotor system complaints were started after receiving two infusions of pembrolizumab. Physical\nexamination revealed both ankle arthritis, mild edema in the pretibial region, tenderness in the muscles and\narthritis in the right f\u0131rst MCP joint. Laboratory examinations showed mild acute phase reactants elevation.\nLower extremity MRI showed diffuse edema in both gastrocnemius muscle and fascia, compatible with\nfasciitis. Pembrolizumab-related fasciitis and seronegative arthritis were diagnosed. Low dose corticosteroid\nwas started and a significant regression was observed in the patient's complaints.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> Inflammatory myositis with fasciitis and inflammatory arthritis in lower extremities appears to\nbe a new adverse effect of pembrolizumab therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574886314666190528121039","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T19:28:41Z","timestamp":1568748521000},"page":"225-229","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma"],"prefix":"10.2174","volume":"14","author":[{"given":"Senol","family":"Kobak","sequence":"first","affiliation":[{"name":"Istinye University Faculty of Medicine, LIV Hospital, Department of Rheumatology, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","volume":"342","author":"Couzin-Frankel J.","year":"2013","unstructured":"Couzin-Frankel J.; Breakthrough of the year 2013. Cancer immunotherapy. Science 2013,342,1432-1433","journal-title":"Science"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"Pardoll D.M.","year":"2012","unstructured":"Pardoll D.M.; The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012,12,252-264","journal-title":"Nat Rev Cancer"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"Robert C.","year":"2014","unstructured":"Robert C.; Ribas A.; Wolchok J.D.; Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 2014,384,1109-1117","journal-title":"Lancet"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.semarthrit.2017.10.018","volume":"47","author":"Kuswanto W.F.","year":"2018","unstructured":"Kuswanto W.F.; MacFarlane L.A.; Gedmintas L.; Mulloy A.; Choueiri T.K.; Bermas B.L.; Rheumatologic symptoms in oncologic patients on PD-1 inhibitors. Semin Arthritis Rheum 2018,47,907-910","journal-title":"Semin Arthritis Rheum"},{"key":"ref=5","author":"Gediz F.","year":"2019","unstructured":"Gediz F.; Kobak S.; Immune checkpoint inhibitors-related rheumatic diseases: What rheumatologist should know? Curr Rheumatol Rev Jan 18. [Epub ahead of print].2019","journal-title":"Curr Rheumatol Rev"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","volume":"151","author":"Sheik A.S.","year":"2015","unstructured":"Sheik A.S.; Goddard A.L.; Luke J.J.; Drug-associated dermatomyositis following ipilimumab therapy: A novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol 2015,151,195-199","journal-title":"JAMA Dermatol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/2326-6066.CIR-15-0186","volume":"4","author":"Khoja L.","year":"2016","unstructured":"Khoja L.; Maurice C.; Chappell M.; Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res 2016,4,175-178","journal-title":"Cancer Immunol Res"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jns.2018.01.030","volume":"387","author":"Bourgeois-Vionnet J.","year":"2018","unstructured":"Bourgeois-Vionnet J.; Joubert B.; Bernard E.; Sia M.A.; Pante V.; Fabien N.; Nivolumab-induced myositis: A case report and a literature review. J Neurol Sci 2018,387,51-53","journal-title":"J Neurol Sci"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/rheumatology\/kex346","volume":"57","author":"Gandiga P.C.","year":"2018","unstructured":"Gandiga P.C.; Wang A.R.; Gonzalez-Rivera T.; Sreih A.G.; Pembrolizumab-associated inflammatory myopathy. Rheumatology (Oxford) 2018,57(2),397-398","journal-title":"Rheumatology (Oxford)"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.autrev.2018.05.002","volume":"17","author":"Narv\u00e1ez J.","year":"2018","unstructured":"Narv\u00e1ez J.; Juarez-L\u00f3pez P.; LLuch J, Narv\u00e1ez JA, Palmero R, Garc\u00eda Del Muro X. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy. Autoimmun Rev 2018,17(10),1040-1045","journal-title":"Autoimmun Rev"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"e000412","DOI":"10.1136\/rmdopen-2016-000412","volume":"3","author":"Calabrese C.","year":"2017","unstructured":"Calabrese C.; Kirchner E.; Kontzias K.; Velcheti V.; Calabrese L.H.; Rheumatic immune-related adverse events of checkpoint therapy for cancer: Case series of a new nosological entity. RMD Open 2017,3(1),e000412","journal-title":"RMD Open"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1634\/theoncologist.2016-0390","volume":"22","author":"Naidoo J.","year":"2017","unstructured":"Naidoo J.; Cappelli L.C.; Forde P.M.; Marrone K.A.; Lipson E.J.; Hans J.; Inflammatory arthritis: A newly recognized adverse event of immune checkpoint blockade. Oncologist 2017,22,627-630","journal-title":"Oncologist"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","volume":"17","author":"Lidar M.","year":"2018","unstructured":"Lidar M.; Giat E.; Garelick D.; Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev 2018,17(3),284-289","journal-title":"Autoimmun Rev"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2174\/1574886313666180508122332","volume":"13","author":"Benfaremo D.","year":"2018","unstructured":"Benfaremo D.; Manfredi L.; Luchetti M.M.; Gabrielli A.; Muscloskeletal and rheumatic diseases induced by immune checkpoint inhibitors: A review of the literature. Curr Drug Saf 2018,13(3),150-164","journal-title":"Curr Drug Saf"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1756-185X.13444","volume":"22","author":"Liew D.F.L.","year":"2019","unstructured":"Liew D.F.L.; Leung J.L.Y.; Liu B.; Cebon J.; Frauman A.G.; Buchanan R.R.C.; Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy. Int J Rheum Dis 2019,22(2),297-302","journal-title":"Int J Rheum Dis"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1053\/j.seminoncol.2018.07.003","volume":"45","author":"Shafqat H.","year":"2018","unstructured":"Shafqat H.; Gourdin T.; Sion A.; Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1\/PD-L1 therapy. Semin Oncol 2018,45(3),156-163","journal-title":"Semin Oncol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"e000714","DOI":"10.1136\/rmdopen-2018-000714","volume":"4","author":"Liepe J.","year":"2018","unstructured":"Liepe J.; Christ L.A.; Arnoldi A.P.; Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open 2018,4(2),e000714","journal-title":"RMD Open"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"Champiat S.","year":"2016","unstructured":"Champiat S.; Lambotte O.; Barreau E.; Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper. Ann Oncol 2016,27(4),559-574","journal-title":"Ann Oncol"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nrrheum.2016.131","volume":"12","author":"van der Vlist M.","year":"2016","unstructured":"van der Vlist M.; Kuball J.; Radstake T.R.; Meyaard L.; Immune checkpoints and rheumatic diseases: What can cancer immunotherapy teach us? Nat Rev Rheumatol 2016,12,593-604","journal-title":"Nat Rev Rheumatol"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","volume":"76","author":"Kim S.T.","year":"2017","unstructured":"Kim S.T.; Tayar J.; Trinh V.A.; Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: A case series. Ann Rheum Dis 2017,76(12),2061-2064","journal-title":"Ann Rheum Dis"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/172311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T16:11:55Z","timestamp":1571415115000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/172311\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886314666190528121039","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-04-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}